See every side of every news story
Published loading...Updated

BTIG Upgrades Progyny to Buy, Citing Rebound in Demand and Market Share Potential

Summary by abbonews.com
BTIG upgraded Progyny (NASDAQ: PGNY), a global leader in women’s health and family building, from Neutral to Buy, setting a 12-month price target of $28. The upgrade follows signs of improving demand after a slowdown in 2024. BTIG noted that Progyny's valuation appears attractive, supported by a strong balance sheet, healthy cash flow, and capable
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

abbonews.com broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.